Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
The review found no eligible studies for this question.
- no estimate extractedStudies not reportedNo studies found
The review found no eligible studies for this question.
Minoxidil 2% showed no clear difference in adverse events compared with minoxidil 5% (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether oral 5‐aminosalicylic acid changes withdrawal due to adverse events compared with comparator 5‐aminosalicylic acid formulation (very low certainty).
It is very uncertain whether glycopeptide (vancomycin or teicoplanin) plus aminoglycoside… changes adverse events compared with beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin) (very low certainty).
Oral 5‐aminosalicylic acid showed no clear difference in adverse events compared with placebo (moderate certainty).
Allopurinol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Minoxidil showed no clear difference in adverse events compared with placebo (low certainty).
Any antibiotic treatment may leads to higher minor adverse events in sexual partner compared with placebo (low certainty).
Fibrinolytics showed no clear difference in serious adverse events compared with placebo (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether antifibrinolytics changes adverse events (any) compared with herbal medicines (very low certainty).
It is very uncertain whether antifibrinolytics changes adverse events (any) compared with levonorgestrel intrauterine system (very low certainty).
Antifibrinolytics showed no clear difference in adverse events (any) compared with no treatment or placebo (low certainty).
Antifibrinolytics may leads to lower adverse events (any) compared with progestogens (low certainty).
The review found no eligible studies for this question.